ESRRB and breast carcinoma: While preliminary, these data suggest that ERRβ2 may be a good prognostic factor in TNBC, and are consistent with the findings we present here that implicate the activated ERRβ2 splice variant as a potent inhibitor of mitotic progression in breast cancer cells, including triple negative models.